EA201400376A1 - Вакцинная терапия - Google Patents

Вакцинная терапия

Info

Publication number
EA201400376A1
EA201400376A1 EA201400376A EA201400376A EA201400376A1 EA 201400376 A1 EA201400376 A1 EA 201400376A1 EA 201400376 A EA201400376 A EA 201400376A EA 201400376 A EA201400376 A EA 201400376A EA 201400376 A1 EA201400376 A1 EA 201400376A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloid
aged
young
individuals
protein
Prior art date
Application number
EA201400376A
Other languages
English (en)
Other versions
EA032494B1 (ru
Inventor
Андреа ПФАЙФЕР
Андреас МУС
Риме Мадани
Павел Васильевич Беличенко
Уилльям Чарлз Мобли
Original Assignee
Ац Иммуне С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ац Иммуне С.А. filed Critical Ац Иммуне С.А.
Publication of EA201400376A1 publication Critical patent/EA201400376A1/ru
Publication of EA032494B1 publication Critical patent/EA032494B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Abstract

В заявке описаны способы лечения, облегчения симптомов и предупреждения связанной с амилоидом патологии у индивидуумов от молодого до среднего возраста с синдромом Дауна (DS). В частности, в заявке описаны фрагменты антигенного пептида, происходящие из амилоидного белка или амилоидоподобного белка, которые предназначены для применения для превентивного лечения связанной с амилоидом патологии у индивидуумов от молодого до среднего возраста с синдромом Дауна.
EA201400376A 2011-09-23 2012-09-21 N-КОНЦЕВОЙ Аβ1-15 АНТИГЕННЫЙ ПЕПТИД ДЛЯ ЛЕЧЕНИЯ ИНДИВИДУУМА С СИНДРОМОМ ДАУНА EA032494B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (2)

Publication Number Publication Date
EA201400376A1 true EA201400376A1 (ru) 2014-09-30
EA032494B1 EA032494B1 (ru) 2019-06-28

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400376A EA032494B1 (ru) 2011-09-23 2012-09-21 N-КОНЦЕВОЙ Аβ1-15 АНТИГЕННЫЙ ПЕПТИД ДЛЯ ЛЕЧЕНИЯ ИНДИВИДУУМА С СИНДРОМОМ ДАУНА

Country Status (21)

Country Link
EP (1) EP2758071B1 (ru)
JP (1) JP6110861B2 (ru)
KR (3) KR20160099732A (ru)
CN (2) CN109847058A (ru)
AU (1) AU2012312126B2 (ru)
BR (1) BR112014006871A2 (ru)
CA (1) CA2811188C (ru)
DK (1) DK2758071T3 (ru)
EA (1) EA032494B1 (ru)
ES (1) ES2712951T3 (ru)
HU (1) HUE041277T2 (ru)
IL (1) IL231564A0 (ru)
MX (1) MX350928B (ru)
MY (1) MY169574A (ru)
PL (1) PL2758071T3 (ru)
PT (1) PT2758071T (ru)
SG (1) SG11201400795UA (ru)
SI (1) SI2758071T1 (ru)
TR (1) TR201901846T4 (ru)
WO (1) WO2013044147A1 (ru)
ZA (1) ZA201402071B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US20220226447A1 (en) 2019-05-21 2022-07-21 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1018883A4 (en) 1997-08-28 2001-05-16 Ajay North America PLANT AND CROP PROTECTION METHODS AND COMPOSITIONS
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2004209981B2 (en) * 2003-02-01 2009-02-26 Janssen Sciences Ireland Uc Active immunization to generate antibodies to soluble A-beta
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TWI379839B (en) * 2003-12-17 2012-12-21 Wyeth Llc Aβ immunogenic peptide carrier conjugates and methods of producing same
NZ552480A (en) * 2004-07-30 2010-01-29 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods of using same
MY181173A (en) * 2005-12-12 2020-12-21 Ac Immune Sa Therapeutic vaccine
TWI453217B (zh) * 2007-06-12 2014-09-21 Ac Immune Sa 抗β類澱粉蛋白單株抗體
SG174871A1 (en) * 2009-03-18 2011-11-28 Ac Immune Sa Method for therapeutic use

Also Published As

Publication number Publication date
ES2712951T3 (es) 2019-05-16
EP2758071A1 (en) 2014-07-30
PT2758071T (pt) 2019-01-11
HUE041277T2 (hu) 2019-05-28
WO2013044147A1 (en) 2013-03-28
SG11201400795UA (en) 2014-10-30
KR20160099732A (ko) 2016-08-22
IL231564A0 (en) 2014-04-30
KR102129220B1 (ko) 2020-07-02
MX2014003325A (es) 2014-05-21
PL2758071T3 (pl) 2019-08-30
CN104039346A (zh) 2014-09-10
KR20190035948A (ko) 2019-04-03
DK2758071T3 (en) 2019-02-18
CN109847058A (zh) 2019-06-07
BR112014006871A2 (pt) 2017-04-04
CA2811188C (en) 2020-04-28
JP2014531455A (ja) 2014-11-27
JP6110861B2 (ja) 2017-04-05
CA2811188A1 (en) 2013-03-23
AU2012312126B2 (en) 2016-11-10
AU2012312126A1 (en) 2014-03-27
KR20160005380A (ko) 2016-01-15
EA032494B1 (ru) 2019-06-28
MY169574A (en) 2019-04-22
NZ622653A (en) 2015-12-24
SI2758071T1 (sl) 2019-01-31
ZA201402071B (en) 2017-08-30
MX350928B (es) 2017-09-26
TR201901846T4 (tr) 2019-03-21
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
EA201590388A1 (ru) Способы лечения таупатии
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201790413A1 (ru) Антитела против tigit
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
EA201591839A1 (ru) Терапевтические пептиды
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
EA201592203A1 (ru) Способы лечения таупатии
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201690898A1 (ru) Способы лечения таупатии
NZ723884A (en) Methods of treating alzheimer’s disease
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA202090683A3 (ru) Способы и композиции для лечения рака
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM